GlassScriptPhysician profile
William R Giles
NPI 1386662419
$3,570.43
in general payments reported to CMS, 2019-2025
26 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.74 · 2022: $162 · 2023: $1,079 · 2024: $1,155 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301 · Education: $95.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.82 |
| Education | $95.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $442.97 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $433.95 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $432.38 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $371.68 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $280.88 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $256.50 | 2023-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.33 | 2023-2025 | Jardiance, Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $163.63 | 2022-2025 | Rexulti, Nuedexta |
| Exact Sciences Corporation | $144.08 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $124.22 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.36 | 2023-2025 | Relistor, Xifaxan, Trulance |
| Dexcom, INC. | $110.03 | 2023-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $93.22 | 2022-2024 | Yupelri |
| Ardelyx, INC. | $54.37 | 2025 | Ibsrela |
| Viatris Specialty LLC | $44.67 | 2025 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $41.69 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $39.37 | 2023 | Xarelto |
| Antares Pharma, INC. | $37.52 | 2024 | Xyosted |
| Teva Pharmaceuticals USA, INC. | $25.32 | 2023 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $23.00 | 2025 | |
| Tactile Systems Technology INC | $20.77 | 2023 | Entre Plus, Flexitouch Plus |
| Amneal Pharmaceuticals LLC | $16.56 | 2024 | Rytary |
| Philips North America LLC | $15.07 | 2025 | Event |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.52 | 2025 | Caplyta |
| Hikma Pharmaceuticals USA | $13.19 | 2023 | Kloxxado, Ryaltris |
| Novartis Pharmaceuticals Corporation | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.